What is apolipoprotein B? Apolipoprotein B or ApoB, is the protein that sits on the surface of every atherogenic lipoprotein particle and measuring it counts those particles directly instead of estimating them from cholesterol mass. That distinction matters because two people with identical LDL cholesterol can carry very different numbers of particles. The particles are what actually lodge in the artery wall. This guide explains what ApoB is, why it beats LDL alone for judging cardiovascular risk and what target to aim for depending on your overall risk picture.
- ApoB counts the actual particles that drive atherosclerosis, while LDL cholesterol estimates cholesterol mass only.
- Two people with identical LDL can carry very different particle counts and very different risk.
- The target depends on context: near 90 mg/dL for average risk, 70 or lower for higher risk, tighter still for known disease.
- ApoB is included in our quarterly Biomarker Audit, so the trend is read every 90 days rather than once a year.
- Treatment decisions follow the particle number and the whole metabolic picture rather than a single cholesterol value.
What ApoB actually measures
Every atherogenic lipoprotein particle, whether it is an LDL particle, a small dense LDL particle, an Lp(a) particle or a VLDL remnant, carries exactly one ApoB protein on its surface. That makes ApoB a direct count of the particle population that can enter the artery wall, rather than an estimate based on the cholesterol those particles happen to be carrying.
Standard lipid panels estimate LDL cholesterol using a formula, usually the Friedewald calculation, that assumes a normal relationship between cholesterol mass and particle number. When triglycerides are high or particle size is unusual, the assumption breaks. A person can have an LDL cholesterol of 100 and an ApoB of 110, which tells a very different story than the cholesterol number alone suggests. The MedlinePlus entry on the ApoB test describes it as a more specific measure of cardiovascular risk than LDL cholesterol alone and the American Heart Association's materials on cholesterol treat particle-level detail as an advanced marker worth measuring in risk that is otherwise hard to pin down.
Why particle count beats cholesterol mass
The atherosclerotic process is physical rather than chemical. Particles cross the endothelium and lodge in the artery wall and the number of particles that do this over decades is what determines plaque burden. Cholesterol mass is a property of the particles, not the thing that does the damage.:::table Why the two numbers disagree Situation | LDL cholesterol says | ApoB says | Why High triglycerides | Underestimates risk | Counts accurately | Friedewald formula breaks down Small dense LDL | Underestimates risk | Counts accurately | Small particles carry less cholesterol each Normal panel, family history | Reassuring | Often elevated | Particle number can be high while mass looks fine Metabolic syndrome | Mixed picture | Usually the truer read | Insulin resistance shifts particle composition :::
The pattern we see most often in practice is the person whose standard panel reads normal and whose ApoB does not. That person is usually a longevity optimizer with a family history of heart disease and a lifestyle that photographs well on a basic panel. The ApoB is the marker that catches them, which is why we include it in the quarterly Biomarker Audit rather than treating it as an add-on.
What target to aim for
The target depends on the overall risk picture rather than on a single universal number. For an average-risk adult, an ApoB near 90 mg/dL is a reasonable ceiling. For someone with a family history of early heart disease or with other risk factors, the target drops to 70 mg/dL or below. For someone with established atherosclerotic disease, the target is tighter still, often 55 mg/dL or below.
The reason the target scales with risk is that the benefit of lowering particle count is proportional to the risk being managed. A patient with established disease gains more from a lower particle count than a healthy twenty-five-year-old does and the clinical protocols we follow reflect that proportionality rather than treating one number as universal.
Lp(a) belongs in this conversation because it is one of the ApoB-containing particles and because it is largely genetically determined and measurable once in a lifetime for risk stratification. We include it in the Biomarker Audit for exactly that reason, as covered in more detail in the definitive guide to Cardiometabolic Optimization.
What is my ApoB and what is my trend? If the answer is that ApoB was never measured, the cardiovascular conversation has been had at a lower resolution than the risk deserves.
What it costs, stated plainly
The Cardiometabolic Optimization Membership is one flat $299 per month. The first charge at checkout is $598, which covers the first two months together: the clinical intake, the first quarterly Biomarker Audit with ApoB and Lp(a) and the full lipid, metabolic and hormone panels and the second month of clinical care while your protocol is built. From month three it is $299 per month, month to month, cancel anytime after the initial commitment.
That fee covers the clinical layer only and stays deliberately separate from the medicine. Any prescription is billed separately by the pharmacy at pharmacy cost with zero markup and no dose-escalation fee. One flat fee for the doctor. Zero markup on the medicine. We make money when you get healthier, not when your dose gets stronger. Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. All labs run through the Beluga Health lab network.
If your family history makes cardiovascular risk the question you came here with, start with the eligibility assessment or read how we approach Cardiometabolic Optimization first.
FAQ
What is ApoB? Apolipoprotein B is the protein on the surface of every atherogenic lipoprotein particle. Measuring it counts those particles directly, which makes it a more specific marker of cardiovascular risk than LDL cholesterol alone.
Why is ApoB better than LDL cholesterol? Because the particles, not the cholesterol mass, are what lodge in the artery wall. Two people with identical LDL cholesterol can carry very different particle counts and the particle count is the truer read of risk.
What is a normal ApoB level? For an average-risk adult, near 90 mg/dL is a reasonable ceiling. Higher-risk patients aim for 70 or below and established disease aims tighter still. The right target depends on the whole risk picture rather than on a universal number.
Can LDL cholesterol be normal while ApoB is high? Yes and it is common. When triglycerides are high or particles are small and dense, the standard estimate undercounts risk. The ApoB catches what the cholesterol number misses.
Is ApoB included in the GoodLife Health Biomarker Audit? Yes. ApoB and Lp(a) are both included in the quarterly Biomarker Audit, read alongside the full lipid, metabolic and hormone panels, because the trend every 90 days is what guides treatment.
Does GoodLife Health treat high cholesterol? Yes, inside the Cardiometabolic Optimization Membership. The quarterly Biomarker Audit tracks the particle-level markers and clinicians build the plan on those labs and the whole metabolic picture.
Related guides
- Cardiometabolic optimization: the definitive guide
- Biomarker audits vs standard blood tests
- ApoB vs LDL: which cholesterol test predicts risk
- Medical weight loss at GoodLife Health
References
- MedlinePlus: Apolipoprotein B test. 2024. medlineplus.gov/lab-tests/apolipoprotein-b-test/
- American Heart Association: Cholesterol. 2024. www.heart.org/en/health-topics/cholesterol